Current utilization trends for beta-blockers in cardiovascular disease.
Beta blockers have repeatedly demonstrated their therapeutic value in the treatment of a variety of diseases; as a result, multiple treatment guidelines advocate the use of beta blockers. Despite these guidelines, the use of beta blockers is remarkably low. Numerous factors that influence the trends of drug use include pharmaceutical advertisements, physician legal concerns, marketing influences, outdated therapeutic contraindications, and patient and physician demographics. Recent primary evidence from randomized clinical trials has demonstrated a significant benefit to patients with heart failure when beta-blocker therapy is added to standard therapy. To ensure proper treatment, continuing efforts must be made to provide patients with appropriate therapy that is proven to reduce the risks of mortality and morbidity.
Kennedy
H L
HL
Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota, USA.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000401:mortality; D004363:Drug Utilization / Q000706:statistics & numerical data*; D019983:Guideline Adherence; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D009203:Myocardial Infarction / Q000188:drug therapy; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D014481:United States / Q000453:epidemiology
D000319:Adrenergic beta-Antagonists